v3.26.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
 [1]
Current assets:    
Cash and cash equivalents $ 1,533,363 $ 570,119
Marketable securities 5,492 17,363
Accounts receivable, net 375,089 139,444
Inventories 59,718 26,753
Prepaid expenses and other current assets 70,944 44,070
Total current assets 2,044,606 797,749
Equity method investments 47,783 79,972
Property and equipment, net 5,042 5,366
Operating lease right-of-use assets 15,746 8,149
Intangible assets, net 25,923 28,077
Other assets 22,686 16,712
Total assets 2,161,786 936,025
Current liabilities:    
Accounts payable 88,258 36,228
Accrued compensation and benefits 66,686 76,703
Accrued research and development liabilities 55,018 41,436
Operating lease liabilities, current portion 1,987 6,192
Deferred revenue, current portion 4,744 7,190
Other current liabilities [2] 212,114 120,222
Total current liabilities 977,237 287,971
Deferred royalty obligations, net [3] 884,053 855,030
Operating lease liabilities, net of current portion 14,645 3,811
Deferred revenue, net of current portion 8,968 13,080
Other long-term liabilities 1,405 244
Total liabilities 3,815,291 3,012,606
Commitments and contingencies (Note 7)
Redeemable convertible noncontrolling interests (1,363) (570)
Stockholders’ deficit:    
Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of June 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 207 202
Treasury stock, at cost; 7,597,172 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 (580,775) (323,276)
Additional paid-in capital 2,170,006 2,057,646
Accumulated other comprehensive income (loss) (95) 12
Accumulated deficit (4,194,163) (3,821,194)
Total BridgeBio stockholders’ deficit (1,662,342) (2,086,610)
Noncontrolling interests 10,200 10,599
Total stockholders’ deficit (1,652,142) (2,076,011) [4]
Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit 2,161,786 936,025
Undesignated Preferred Stock    
Stockholders’ deficit:    
Undesignated preferred stock and Series A preferred stock 0 0
Series A Cumulative Convertible Participating Preferred Stock    
Stockholders’ deficit:    
Undesignated preferred stock and Series A preferred stock 942,478 0
2027 Notes, net    
Current liabilities:    
2027 Notes, net 548,430 0
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 0 547,015
2029 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 742,437 740,890
2031 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes 566,013 564,565
2033 Notes, net    
Current liabilities:    
2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes $ 620,533 $ 0
[1] The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.
[2] Including related party amounts of nil and $2,003 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).
[3] Including related party amounts of nil and $204,650 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).
[4] The consolidated balances as of December 31, 2025 and 2024 are derived from the audited consolidated financial statements as of those dates.